No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli.

Antimicrobial Agents and Chemotherapy
Louisa D'LimaDmitri Debabov

Abstract

Twenty-five serial passages of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus and 50 passages of methicillin-resistant Staphylococcus aureus resulted in no significant increase in NVC-422 MICs, while ciprofloxacin MICs increased 256-fold for E. coli and 32-fold for P. aeruginosa and S. aureus. Mupirocin, fusidic acid, and retapamulin MICs for MRSA increased 64-, 256-, and 16-fold, respectively. No cross-resistance to NVC-422 was observed with mupirocin-, fusidic acid-, and retapamulin-resistant strains.

References

May 23, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G L Archer
May 1, 1999·Antimicrobial Agents and Chemotherapy·T A DaviesP C Appelbaum
Oct 29, 2000·The Pediatric Infectious Disease Journal·S B Levy
Mar 26, 2004·Nature Reviews. Microbiology·James B KaperHarry L Mobley
May 26, 2006·Antimicrobial Agents and Chemotherapy·Lisa FriedmanJared A Silverman
Oct 8, 2008·Antimicrobial Agents and Chemotherapy·Daniel R GentryDavid J Holmes
Aug 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean B PatelJohn A Jernigan
Sep 22, 2010·Antimicrobial Agents and Chemotherapy·Hsiao-Jan ChenLee-Jene Teng
Feb 24, 2011·Antimicrobial Agents and Chemotherapy·Catherine ClarkKlaudia Kosowska-Shick
Mar 23, 2011·Antimicrobial Agents and Chemotherapy·Lu WangBehzad Khosrovi
Jul 13, 2011·Frontiers in Microbiology·Keith Poole
Aug 13, 2011·Current Opinion in Pharmacology·José Luis MartínezDan I Andersson

❮ Previous
Next ❯

Citations

Dec 5, 2012·Antimicrobial Agents and Chemotherapy·Andreas JekleDmitri Debabov
Jan 9, 2013·Antimicrobial Agents and Chemotherapy·Waldemar GottardiMarkus Nagl
Jun 3, 2018·Therapeutic Advances in Respiratory Disease·Roland ArnitzMarkus Nagl
Feb 23, 2017·Antimicrobial Agents and Chemotherapy·Martina GruberMichaela Lackner
May 18, 2017·Frontiers in Microbiology·Lilit TonoyanVincent O'Flaherty
Feb 28, 2021·Journal of Applied Microbiology·C AnichM Nagl
Aug 28, 2021·Antibiotics·Victoria GrimusMarkus Nagl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.